Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1474-1482

  Gogali, Foteini ^a   Paterakis, George ^b   Rassidakis, George Z ^a   Kaltsas, Gregory ^a   Liakou, Chrysoula I ^a   Gousis, Panagiotis ^c   Neonakis, Evangelos ^d   Manoussakis, Menelaos N ^a   Liapi, Charis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NODULAR GOITER; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYROID PAPILLARY CARCINOMA; TISSUE CHARACTERIZATION; TUMOR IMMUNITY;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; GOITER, NODULAR; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; THYROID GLAND; THYROID NEOPLASMS;

EID: 84860762023     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1838     Document Type: Article

References (43)

1. Mazzaferri EL 1990 Thyroid cancer. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. Philadelphia: JB Lippincott; 319-331
2. Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J 1991 Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133-147
3. Kramer JB, Wells Jr SA 1989 Thyroid carcinoma. Adv Surg 22:195-224
4. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
5. Burke JP, Hay ID, Dignan F, Goellner JR, Achenbach SJ, Oberg AL, Melton 3rd LJ 2005 Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999. Mayo Clin Proc 80:753-758
6. Muller-Hubenthal B, Azemar M, Lorenzen D, Huber M, Freudenberg MA, Galanos C, Unger C, Hildenbrand B 2009 Tumor biology: tumor-associated inflammation versus antitumor immunity. Anticancer Res 29:4795-4805
7. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ 2003 NK cells and the tumor microenvironment: implications for NK-cell function and antitumor activity. Trends Immunol 24:603-609
8. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287-296
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Break-down of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164
10. + Tregs and immune control. J Clin Invest 114:1209-1217
11. + (hi) regulatory T cells with VEGF and TNF α in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108:421-427
12. +/PD-1 T lymphocytes coinfiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57
13. + regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6:432-438
14. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Kloppel G, Kabelitz D, Kalthoff H 2007 Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344-8350
15. + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18:1115-1122
16. Hori S, Nomura T, Sakaguchi S 2003 Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061
17. + regulatory T cells. Nat Immunol 4:330-336
18. + T regulatory cells. Nat Immunol 4:337-342
19. Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F 2010 Human FOXP3 and cancer. Oncogene 29:4121-4129
20. Gambineri E, Torgerson TR, Ochs HD 2003 Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15:430-435
21. Torgerson TR, Ochs HD 2007 Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 120:744-750; quiz 751 = 752
22. Ziegler SF 2006 FOXP3: of mice and men. Annu Rev Immunol 24:209-226
23. + Tregs. J Clin Invest 115:2904-2913
24. + T reg cells. J Exp Med 203:1701-1711
25. Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L, Goepfert PA, Zajac AJ 2005 Cutting edge: emergence of CD127high functionally competent memory T cells in compromised by high viral loads and inadequate T cell help. J Immunol 174:5926-5930
26. + memory T cell subsets. Proc Natl Acad Sci USA 101:5610-5615
27. Li J, Huston G, Swain SL 2003 IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 198:1807-1815
28. + regulatory T cells. Trends Immunol 27:541-544
29. Clark OH, Greenspan FS, Dunphy JE 1980 Hashimoto's thyroiditis and thyroid cancer: indications for operation. Am J Surg 140:65-71
30. Aguayo J, Sakatsume Y, Jamieson C, Row VV, Volpe R 1989 Nontoxic nodular goiter and papillary thyroid carcinoma are not associated with peripheral blood lymphocyte sensitization to thyroid cells. J Clin Endocrinol Metab 68:145-149
31. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458-463
32. Ford AL, Foulcher E, Goodsall AL, Sedgwick JD 1996 Tissue digestion with dispase substantially reduces lymphocyte and macrophage cell-surface antigen expression. J Immunol Methods 194:71-75
33. Loken MR, Wells DA 1994 Immunofluorescence of surface markers. In: Ormerod MG, ed. Flow cytometry: apractical approach. 2nd ed. Oxford, UK: Oxford University Press; 67-91
34. + regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95:2325-2333
35. Mülle RS, Poehnert D, Müller JA, Scheumann GW, Koch M, Luck R 2010 Regulatory T cells in peripheral blood, lymph node, and thyroid tissue in patients with medullary thyroid carcinoma. World J Surg 34:1481-1487
36. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M 2008 T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 105:7797-7802
37. Marazuela M, García-Lopez MA, Figueroa-Vega N, de la Fuente H, Alvarado-Sanchez B, Monsivais-Urenda A, Sanchez-Madrid F, Gonzalez-Amaro R 2006 Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab 91:3639-3646
38. Modi J, Patel A, Terrell R, Tuttle RM, Francis GL 2003 Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab 88:4418-4425
39. Brittenden J, Heys SD, Ross J, Eremin O 1996 Natural killer cells and cancer. Cancer 77:1226-1243
40. Ghiringhelli F, Menard C, Martin F, Zitvogel L 2006 The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 214:229-238
41. + regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 8:59-66
42. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD 2006 Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 106:2158-2164
43. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA 2005 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053